NEW YORK (GenomeWeb News) – AdvanDx, a provider of molecular diagnostics for pathogen identification, said today that it has closed a $12 million Series B-1 financing round.

The financing will go toward expansion of the Woburn, Mass.-based company's product offerings and its sales and marketing operations in the US and abroad, it said.

Merck Global Health Innovation Fund led the round and was joined by existing investors SLS Ventures and LD Pensions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.